Immunogenic death of colon cancer cells treated with oxaliplatin

Oncogene

Volumn 29, Issue 4, 2010, Pages 482-491

  Tesniere, A ^a,b,c   Schlemmer, F ^a,b,c   Boige, V ^b   Kepp, O ^a,b,c   Martins, I ^a,b,c   Ghiringhelli, F ^a,d   Aymeric, L ^a,b,c   Michaud, M ^a,b,c   Apetoh, L ^a,b,c   Barault, L ^e,f   Mendiboure, J ^b   Pignon, J P ^b   Jooste, V ^f,g   Van Endert, P ^a   Ducreux, M ^b,c   Zitvogel, L ^a,b,c   Piard, F ^e,f   Kroemer, G ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f Chu   (France)

^g Registre Bourguignon des Cancers Digestifs   (France)

Author keywords

Apoptosis; Calreticulin; Dendritic cells; HMGB1; OXP; TLR4

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETICULIN; CISPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; OXALIPLATIN; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; PLATINUM COMPLEX; TLR4 PROTEIN, MOUSE;

ADULT; AGED; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DEATH; COLON CANCER; CONTROLLED STUDY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN SECRETION; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLON TUMOR; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

MURINAE; MUS;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALRETICULIN; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC; PROGNOSIS; TOLL-LIKE RECEPTOR 4;

EID: 75749147533     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.356     Document Type: Article

References (35)

1. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE et al. (2002). Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186: 1522-1525.
2. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. (2007a). The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 220: 47-59.
3. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. (2007b). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
4. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al. (2000). TLR4 mutations are associated with endotoxin hyporespon-siveness in humans. Nat Genet 25: 187-191.
5. Blachere NE, Darnell RB, Albert ML. (2005). Apoptotic cells deliver processed antigen to dendritic cells for cross-presentation. PLoS Biol 3: e185.
6. Bouche, Castaing M, Etienne PL, Texereau P, Auby D, Bedenne L et al. (2007). Randomized strategical of chemotherapy in metastatic colorectal cancer (FFCD 2000-05): preliminary results. J Clin Oncol 25: 4069.
7. Camus M, Tosolini M, Mlecnik B, Pages F, Kirilovsky A, Berger A et al. (2009). Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res 69: 2685-2693.
8. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N et al. (2005). Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701.
9. Castedo M, Coquelle A, Vitale I, Vivet S, Mouhamad S, Viaud S et al. (2006). Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Ann NY Acad Sci 1090: 35-49.
10. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N et al. (2007). TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 104: 16645-16650.
11. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
12. Hsu WM, Hsieh FJ, Jeng YM, Kuo ML, Chen CN, Lai DM et al. (2005). Calreticulin expression in neuroblastoma\-a novel independent prognostic factor. Ann Oncol 16: 314-321.
13. Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584.
14. Laane E, Tamm KP, Buentke E, Ito K, Khahariza P, Oscarsson J et al. (2009). Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ.
15. Matzinger P. (2002). The danger model: a renewed sense of self. Science 296: 301-305.
16. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. (2008). Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 57: 197-206.
17. Muggia FM, Fojo T. (2004). Platinums: extending their therapeutic spectrum. J Chemother 16(Suppl 4): 77-82.
18. Netea-Maier RT, Hunsucker SW, Hoevenaars BM, Helmke SM, Slootweg PJ, Hermus AR et al. (2008). Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res 68: 1572-1580.
19. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P et al. (2007a). Calreticulin exposure is required for the immuno-genicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 14: 1848-1850.
20. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. (2007b). Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61. (Pubitemid 46067386)
21. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R et al. (2005). Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353: 2654-2666.
22. Panaretakis T, Joza N, Modjtahedi N, Vitale I, Durchschlag M, Fimia GM et al. (2008). The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ 15: 1499-1509.
23. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. (2009). Mechanisms of pre-apoptotic calreticu-lin exposure in immunogenic cell death. EMBO J 28: 578-590.
24. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. (2006). High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290: C917-C924.
25. Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P et al. (2009). Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458: 899-903.
26. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ et al. (2008). Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118: 2098-2110.
27. Savill J, Fadok V. (2000). Corpse clearance defines the meaning of cell death. Nature 407: 784-788.
28. Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P et al. (1999). Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96: 14888-14893.
29. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, Panaretakis T, Kepp O et al. (2008). Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol 20: 504-511.
30. Toquet C, Jarry A, Bou-Hanna C, Bach K, Denis MG, Mosnier JF et al. (2007). Altered calreticulin expression in human colon cancer: maintenance of calreticulin expression is associated with mucinous differentiation. Oncol Rep 17: 1101-1107.
31. Wang D, Lippard SJ. (2005). Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
32. Wright CA, Kozik P, Zacharias M, Springer S. (2004). Tapasin and other chaperones: models of the MHC class I loading complex. Biol Chem 385: 763-778.
33. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y et al. (2006). Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 177: 3582-3589.
34. Zhang Y, Williams DB. (2006). Assembly of MHC class I molecules within the endoplasmic reticulum. Immunol Res 35: 151-162.
35. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. (2008). The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118: 1991-2001.